Arkolith/Insider Trading/XLO/Form 4

Frankenfield Christopher James

Chief Financial OfficerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Jan 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7K
Net Open-Market Flow
-$7K
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2025Sell(S)7K$0.98$7K12K
Jan 1, 2025Option exercise(M)19K——19K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 1, 2025Grant(A)251K—$0251K
Jan 1, 2025Option exercise(M)19K—$058K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-000407) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML